Immatics (IMTX) Stock News, May-Dec 2025

Immatics (NASDAQ: IMTX) agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering, generating expected gross proceeds of $125 million before underwriting discounts and offering expenses.

The offering is expected to close on December 8, 2025, subject to customary closing conditions; a registration statement was declared effective on April 3, 2025. Jefferies, Leerink Partners and Cantor are joint book‑running managers. The shares are being offered only by prospectus supplement and accompanying prospectus.

Immatics (NASDAQ: IMTX) reported Q3 2025 results and a business update on November 17, 2025, highlighting clinical progress across its PRAME franchise and a cash position of $505.8M as of September 30, 2025.

Key clinical highlights: anzu-cel (IMA203) Phase 3 SUPRAME trial ongoing with interim and final PFS analyses expected in 2026, planned BLA submission in 1H 2027 and potential launch in 2H 2027. Phase 1b uveal melanoma update (n=16): cORR 67%, mDOR 11.0 months, mPFS 8.5 months, mOS not reached at 14.3 months. IMA203CD8 GEN2 dose escalation updates planned for Dec 11, 2025.

Bispecifics: IMA402 PRAME showed RP2D-range cORR 30% (6/20) with ongoing Phase 1b expansions in 2026; IMA401 MAGEA4/8 demonstrated clinical proof-of-concept with activity in multiple indications. Q3 financials: revenue $6.1M, R&D $55.4M, net loss $59.3M.

Immatics (NASDAQ: IMTX) reported Phase 1a dose‑escalation data for its next‑generation TCR Bispecifics, IMA402 (PRAME) and IMA401 (MAGEA4/8), and announced Phase 1b plans on November 12, 2025. IMA402 at the RP2D range (10–30 mg) produced a 30% cORR (6/20) across indications, including 29% in melanoma (4/14), with deep durable responses (two complete metabolic responses ongoing 8 and 18 months). Median PFS was 4.8 months (mFU 6.8); 1‑year OS rate was 94%. IMA401 at ≥1 mg showed activity: 25% cORR in head and neck and 29% in melanoma, with a longest response >2 years. Both candidates showed favorable tolerability; provisional RP2D ranges were identified (IMA402: 10–30 mg; IMA401: 1–2 mg).

Immatics (NASDAQ: IMTX) appointed Amie Krause as Chief People Officer effective October 27, 2025.

Ms. Krause brings more than 20 years of global biopharma HR experience, including prior roles at Dompé, Revance Therapeutics, Atara Biotherapeutics and Amgen. The newly established CPO role will lead human resources, organizational development and operations as Immatics transitions to a commercial-stage company and prepares for potential commercialization of its lead PRAME cell therapy candidate, anzu-cel.

Immatics (NASDAQ: IMTX) reported updated Phase 1b data for one-time anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 metastatic uveal melanoma patients presented at ESMO 2025 on October 20, 2025.

Key outcomes: cORR 67% (10/15), mDOR 11.0 months, mPFS 8.5 months (median follow-up 10.4 months) and mOS not reached at 14.3 months mFU; median liver target lesion shrinkage -49.6%. Safety showed mostly Grade 1–2 CRS; Grade 3 CRS 18.8% and no anzu-cel–related Grade 5 events. A Phase 2 cohort (~30 patients) in metastatic uveal melanoma has been initiated.

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on PRAME targeting, has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately. Dr. Ramanan brings over 25 years of experience from prominent companies including Seagen, Gilead Sciences, and Amgen.

The new CFO joins from Anthos Therapeutics, where he previously served as CFO, and succeeds Arnd Christ. Dr. Ramanan's appointment comes at a crucial time as Immatics prepares for the commercial launch of anzu-cel, their PRAME cell therapy for metastatic melanoma patients. His extensive experience includes facilitating product launches, establishing global operations, and enabling corporate transactions.

Immatics (NASDAQ: IMTX) reported Q2 2025 financial results and provided updates on its PRAME-targeting therapies. The company's lead candidate, anzu-cel, demonstrated strong results in Phase 1b melanoma trials with a 56% confirmed objective response rate and 12.1 months median duration of response. The global Phase 3 SUPRAME trial is progressing with interim and final analyses expected in 2026.

Financial highlights include cash position of $560.5 million providing runway into 2H 2027, though Q2 showed increased net loss of $82.4 million versus $21.1 million year-over-year. R&D expenses rose to $52.9 million, reflecting advancement of clinical programs.

The company announced CFO Arnd Christ's planned departure and is searching for a replacement. Multiple clinical updates across its pipeline are expected in Q4 2025, including data from IMA203CD8, IMA402, and IMA401 programs.

Immatics presented extended Phase 1b trial data for IMA203 PRAME cell therapy at ASCO 2025, showing strong efficacy in metastatic melanoma patients. The trial of 33 heavily pretreated patients demonstrated a 56% confirmed objective response rate (cORR) and median duration of response of 12.1 months. Notably, cutaneous melanoma patients showed 50% cORR with duration not reached, while uveal melanoma patients achieved 67% cORR with 11-month duration. The therapy maintained a favorable safety profile, with manageable cytokine release syndrome and low neurotoxicity. Based on these positive results and PRAME's high prevalence in melanoma (90-95%), Immatics is advancing IMA203 in the Phase 3 SUPRAME trial for previously treated cutaneous melanoma patients, with BLA submission targeted for Q1 2027.

Immatics (NASDAQ: IMTX) reported Q1 2025 financial results and provided updates on its PRAME-targeted cancer immunotherapy programs. The company's lead candidate, IMA203 PRAME cell therapy, is advancing in the Phase 3 SUPRAME trial for melanoma, with enrollment expected to complete in 2026. Immatics maintains a strong financial position with $588.1 million in cash and equivalents, providing runway into 2H 2027. Key developments include FDA IND clearance for a combination trial with Moderna's PRAME therapy and ongoing trials for multiple product candidates. The company reported a net loss of $43.2 million for Q1 2025, compared to $2.4 million in Q1 2024, primarily due to lower revenue and forex losses. R&D expenses increased to $45.3 million from $34.7 million year-over-year, reflecting advancement in clinical trials. The company will present updated IMA203 melanoma data at the 2025 ASCO Annual Meeting.